Jincheng Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 139 million yuan. The company's total operating revenue was 1.447 billion yuan, and net cash inflow from operating activities was 194 million yuan. The latest gross margin was 35.36 percent, down 0.77 percentage points from the same period last year, and the latest return on equity was 3.71 percent. The company's diluted earnings per share was 0.37 yuan, and the asset-liability ratio was 25.43 percent.
Shandong Jincheng Pharmaceutical and Chemical Co LtdInterim report shows net profit of 139 million yuan, but no comparison to expectations or prior period, making impact unclear.